The scheme, being delivered for Cambridge Medipark Limited, will consist of a three-storey laboratory building and a four-storey office building, connected by an atrium link. Once complete, the scheme will provide around 100,000sq ft of office and laboratory space, and will be occupied by Abcam, a global leader in the supply of life science research tools.
Works are due to begin on site in March 2017 with a scheduled completion date of late 2018.
The new site will allow Abcam to combine its three current facilities in Cambridge into one new state-of-the-art global headquarters.
Peter Young, Kier executive director, said: “This is another prestigious win for Kier in the biotech sector, building on our sector-leading expertise, as well as reaffirming our track record across Cambridge.
“Kier has extensive experience delivering specialist research facilities, and we are proud to be playing a key role in developing Cambridge Biomedical Campus – a world-renowned centre of clinical and healthcare excellence.”
Kier has a long standing track record of delivering a wide range of key projects for both the public and private sectors across Cambridgeshire, with current schemes in the area including a £79 million laboratory for the University of Cambridge, Kier’s 23rd project with the University.